Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease

US7381537B2 · kind B2 · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Hans-Ulrich Demuth · Halle (Saale), DE
• Torsten Hoffmann · Weil am Rhein, DE
• Andre Niestroj · Halle (Saale), DE
• Stephan Schilling · Halle (Saale), DE
• Ulrich Heiser · Halle (Saale), DE

Key dates

• Filing date: May 5, 2004
• Grant date: Jun 3, 2008
• Expiry date: Jan 29, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6506
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screeing for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.